Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Dr Ryan Magee graduates today with a PhD in Biological Sciences, having developed a faster, cheaper method to track a major ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

A breakthrough study from Seoul suggests the trillions of microbes inside us may be silently driving the world’s leading ...